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Abstract
Background:  Although staphylokianse (SAK) is among the most promising blood dissolving
agents, it is far from ideal. It is interesting to hypothesize that the clot lysis efficacy of SAK can be
enhanced with direct active platelet binding ability, and at the same time the rethrombosis
complication after successful recanalization can be minimized with an antiplatelet aggregation
activity. The present study was performed to characterize the functional properties of RGD-SAK,
a novel mutant of staphylokinase (SAK).
Results: By using site-directed mutagenesis, an Arg-Gly-Asp (RGD) motif was engineered in the
staphylokinase (SAK). This mutant of SAK designated RGD-SAK was expressed, purified and
characterized. Biochemical analysis indicated that RGD-SAK maintained the similar structure and
the fibrinolytic function of SAK. Measurement of platelet binding activity in vitro demonstrated that
RGD-SAK had a much higher affinity with platelets than SAK. In vitro platelet-rich clot lysis assay
demonstrated that the engineered mutant outperformed the non-manipulated SAK. The time
required for 50% platelet-rich clot lysis and the concentration required to obtain 50% clot lysis
(C50) were reduced significantly across different concentrations of RGD-SAK comparing with SAK.
Meanwhile, RGD-SAK was found to inhibit ADP-induced platelet aggregation in a concentration-
dependent manner while SAK had negligible effect on platelet aggregation.
Conclusion: RGD-SAK possessed the bifunction to target platelet-rich clots and to block platelets
aggregation, and thus may serve as a more potential thrombolytic agent with platelet-targeted
thrombolytic and antiplatelet aggregation activities in compared with SAK.
Background
Acute myocardial infarction is among the most prominent
causes of death in the Western world. It is commonly
caused by the formation of a pathologic clot that results in
obstructing the blood flow to heart tissues. Staphyloki-
nase (SAK), a 136-amino acid protein from certain lys-
ogenic  Staphylococcus aureus strains, is a plasminogen
activator and a promising blood clot-dissolving agent
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with clinical potency that is at least as good as tPA [1,2].
SAK does not bind directly to fibrin, it can bind indirectly
through the fibrin binding of plasmin(ogen) by forming
a 1:1 stoichiometric SAK-plasmin(ogen) complex. The
resulting SAK-plasmin complex can then function as the
plasminogen activator to convert plasminogen to plasmin
for clot lysis [3]. Although staphylokianse (SAK) is among
the most promising blood dissolving agents, it is far from
ideal. Recently, some studies have reported that, SAK
could not mediate early reperfusion in 38% of treated
patients and thrombolytic therapy employing staphyloki-
nase is limited by rethrombosis of the very arteries being
opened, which follows in a small but significant number
of patients [1-3]. Development of more potent and faster-
acting thrombolytic agents that can speed up the clot lysis
process and have a lower rethrombosis rate would be
desirable.
Now it is well known that platelets play a pivotal role in
arterial thrombosis. Platelet-rich rather than fibrin-rich
thrombosis was found to be responsible for many acute
complications of angioplasty [4]. Meanwhile, studies
indicated that the reformed secondary clots are usually
platelet-rich after thrombolytic therapy [5]. Hence, it is
interesting to hypothesize that the clot lysis efficacy of
SAK can be enhanced by the application of the manipu-
lated version of SAK that simultaneously targeted dissolve
the platelet-rich clot and inhibit the reformation of blood
clots by preventing platelets aggregation.
On activated platelets, the binding of surface glycoprotein
GPIIb/IIIa to fibrinogen mediates platelet aggregation [6].
GPIIb/IIIa receptor antagonist, such as Arg-Gly-Asp
(RGD) peptide had been proved to have obvious
antiplatelet activity in thrombus formation experiments
[7,8]. In order to improve the thrombolytic potential of
SAK, as well as to introduce the antiplatelet activities, the
mutant of SAK has been constructed. We substituted K35
with Arg to constitute a RGD motif, resulting in a novel
SAK variant, designated as RGD-SAK, which was supposed
to be recognized by the activated GPIIb/IIIa on the surface
of platelet membrane. However, it is not very clear
whether the engineered mutant obtain the hypothesized
effects. In this study, this mutant RGD-SAK was con-
structed and over-expressed in E coli. Biochemical proper-
ties, platelet-targeted thrombolysis, and antiplatelet
aggregation of the purified target protein were deter-
mined.
Results
Construction, expression and purification of RGD-SAK
Using PCR-mediated site-directed mutagenesis, the SAK
variant RGD-SAK was constructed with Arg in place of K35,
and the desired mutant was identified by DNA sequencing
(Fig. 1A). After temperature induction, RGD-SAK was
over-expressed due to the temperature inducible pL and
pR promoter in the expression vector pLY-4. SDS-PAGE
showed that the target protein was expressed after 0.5 h of
induction and reached peak after 2.5 h (Fig. 1B). The pro-
tein was isolated by homogenization and purified by
sequential chromatography through SP-Sepharose,
Sephadex G-50, and Q-Sepharose (Fig. 1C). High purity
protein was obtained (over 98% by densitometric scan-
ning). Western blot (Fig. 1D) revealed that the RGD-SAK
protein had a similar antigen binding capacity to SAK.
Using known concentrations of pure SAK as the standard,
the yield per liter culture of purified RGD-SAK was esti-
mated to be 0.3 g and more than 60% was recovered in
purification.
Physicochemical and biological characterization of 
purified RGD-SAK
To analyse the homogeneity of the puried RGD-SAK, RP-
HPLC analysis was performed and purity analysis gave a
single symmetrical peak with a purity > 98%. No signifi-
cant peaks of impurities were observed at the RP-HPLC
spectrum (Fig. 2A). Molecular mass spectrometric deter-
mination showed that the mono-protonated RGD-SAK
molecule had a molecular weight of 15.4 KDa (Fig. 2B),
which agreed very well with the apparent molecular mass
(15.4 KDa).
To explore the structure of RGD-SAK, the purified sample
was subjected to both N-terminal sequencing by the
Edman degradation procedure and far-UV CD spectrum
analysis. Sequencing of the first fifteen amino acid resi-
dues from the RGD-SAK (SSSFDKGKYKKGDDA)
matched exactly with the mature SAK sequence. Analysis
of the far-ultraviolet CD spectra (Fig. 2C) showed that
SAK comprised 18.2% α-Helix, 36.7% β-Sheet, 45.0%
turns and random coils while RGD-SAK comprised 19.3%
α-Helix, 36.9% β-Sheet, 43.9% turns and random coils.
These results revealed that the secondary structure of the
two proteins were very similar and suggested that the sub-
stitution of K35with Arg did not change the secondary
structure of SAK significantly.
The produced RGD-SAK was evaluated for safety and fibri-
nolytic potencies. The purified, sterilized preparations
were found to contain low endoxin levels (< 3 EU/mg),
which accorded with the clinical injection grade, and were
devoid of acute toxicity in mice after intravenous bolus
injection at a dose of 3 mg per mice in groups of 5 mice.
Fibrinolytic activity of RGD-SAK was also determined on
the fibrin plate (Fig. 2D). Comparing with the standard
SAK, the fibrinolytic activity of RGD-SAK was 120,000 IU/
mg, which was at least equal to or slightly higher than
SAK. The result revealed that the introduction of RGD
sequence into SAK had not altered its fibrinolytic activity.
The plasminogen activation rate (determined by kcat/Km,BMC Molecular Biology 2007, 8:88 http://www.biomedcentral.com/1471-2199/8/88
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Production of an engineered staphylokinase-based RGD-SAK Figure 1
Production of an engineered staphylokinase-based RGD-SAK. (A) Amino acid residues and nucleotide sequences of 
SAK and RGD-SAK are shown. The lys35 has been substituted with Arg to constitute a RGD motif and sequence analysis con-
firmed the successful mutagenesis. (B) Coomassie blue-stained 15% SDS-PAGE showing expression of RGD-SAK. Lane M, pro-
tein marker; lanes 1–6, induced for 0, 0.5, 1, 1.5, 2, 2.5 h. (C) Purification of recombinant protein RGD-SAK. Lane M, protein 
marker; lane 1, cytosol fractions; lane 2, purification after SP-Sepharose; lane 3, purification after Sephadex G-50; lane 4, purifi-
cation after Q-Sepharose. (D) Western blot analysis with polyclonal anti-SAK antibodies.BMC Molecular Biology 2007, 8:88 http://www.biomedcentral.com/1471-2199/8/88
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Km represents the Michaelis constant, kcat represents the
catalytic rate constant) was also examined. In mixtures of
plasminogen with an equimolar SAK, the active site, as
monitored with the chromogenic substrate S-2251, is rap-
idly exposed. Using this formed SAK-plasmin complex,
the kinetic parameters for the activation of plasminogen
were determined. Lineweaver-Burk analysis of the hydrol-
ysis of S-2251 by plasmin-SAK or plasmin-RGD-SAK indi-
cated that the kcat/Km values are comparable (0.033, 0.037
respectively. Table 1), revealing that RGD-SAK has SAK-
like plasminogen activation property.
Fibrin and platelet binding assay
To assess the fibrin binding ability of RGD-SAK, ELISA
experiments with immobilized fibrin were performed.
The results (Fig. 3A) showed that a weak fibrin binding
occurred to both SAK and RGD-SAK, which showed no
significantly statistic difference at a final concentration of
200 nM. In contrast, to examine the possible platelet-tar-
geted binding ability of RGD-SAK due to the presence of
RGD sequence, the in vitro platelet binding assay was per-
formed. Data showed that the platelet-targeted binding
quantity of RGD-SAK was much higher than that of SAK
at various examined concentrations (P < 0.01, Fig. 3B).
Physicochemical and biological properties of RGD-SAK Figure 2
Physicochemical and biological properties of RGD-SAK. (A) HPLC analysis of RGD-SAK. A single symmetrical peak 
with a purity > 98% was indicated in the HPLC analytical chart. (B) Molecular mass determination of purified RGD-SAK by 
MALDF-TOF mass spectrometry. Peaks corresponding to various protonated RGD-SAK species are marked. The mass analy-
sis determined that the RGD-SAK has a molecular weight of 15.4 KDa. (C) The secondary structure contents of RGD-SAK 
and SAK analyzed by far-UV CD spectrum. The secondary structure revealed by the curve of the two proteins were very sim-
ilar. (D) RGD-SAK fibrinolysis activity assayed on fibrin plate. The numbers above the well represent various concentration of 
samples. 1–5 represent various concentrations of standard SAK (6.5 IU, 12.5 IU, 25 IU, 50 IU, 100 IU/well, respectively). Dupli-
cate wells (6–10) corresponding to 1–5 were included. 11–13 represent various diluted RGD-SAK determined by comparing 
with the standard SAK. Three duplicated sets (14–16, 17–19, 20–22) of RGD-SAK corresponding to 11–13 were also shown.BMC Molecular Biology 2007, 8:88 http://www.biomedcentral.com/1471-2199/8/88
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ELISA for platelet binding also indicated that RGD-SAK
could bind the active platelet in a dose dependent man-
ner. As shown in the same figure, SAK almost had no
platelet-binding activity.
Fibrin clot and platelet-rich clot lysis assay
The efficiency of fibrin clot lysis was investigated on the
ELISA plates by calculating the time required for 50%
fibrin clot lysis (T50%). Data showed (Fig. 4A, Table 2) that
the fibrinolytic efficiencies of the two proteins on the
fibrin clot were not significantly different at various exam-
ined concentrations, consistent with their similar fibrinol-
ysis activity assayed on fibrin plate. To examine whether
the enhanced active platelet binding ability by RGD-SAK
would lead to a faster clot lysis, we carried out platelet-rich
clot lysis experiments which partially simulate the physi-
ology situation. The time required for 50% platelet-rich
clot lysis (T50%) by SAK (118 ± 3.4 min) was obviously
longer (SAK vs RGD-SAK, P < 0.01) than that by RGD-SAK
(57 ± 6.6 min) at the final concentration of 200 nM (Fig.
4B). The differences in T50% values between SAK and RGD-
SAK were also dramatic (RGD-SAK vs SAK, P < 0.01) at the
lower concentrations (50, 100 nm, table 2). The results in
table 3 indicated that in comparison with SAK, the T50% of
RGD-SAK was shortened by 1.75, 1.57 and 2.07 folds
respectively at the corresponding concentrations (50, 100
and 200 nm). The degree of thrombolysis by different
amounts of SAK and RGD-SAK was also determined
graphically from plots of clot lysis versus the concentra-
tion of corresponding protein. Equieffective concentra-
tions of test compound (C50, causing 50% fibrin clot lysis
in 3 hours) determined from plots of clot lysis at 3 hours
versus the concentration were 80 ± 8.5 nM for SAK, 76 ±
8.3 nM for RGD-SAK, which were not statistically different
in this system (Table 2). 50% thrombolysis C50 in 2 hours
required 200 ± 8.3 nM of SAK and 38 ± 3.9 nM of RGD-
SAK, as determined by interpolation, thus the thrombo-
lytic effect of RGD-SAK in this system was about 5.3 times
shorter than that of SAK (Table 2).
Antiplatelet aggregation assay
It is predicted from the molecular design that the bifunc-
tional RGD-SAK not only possesses the fibrinolytic activ-
ity, but may also inhibit the platelet aggregation. This was
testified by the antiplatelet aggregation assay in vitro (Fig.
5). A significantly higher inhibitory effect of RGD-SAK on
platelet aggregation stimulated by ADP (10 µM) or colla-
gen (1 µg/ml) or thrombin (1 U/ml) was obtained com-
pared with that of SAK, which had negligible effect on
platelet aggregation. The dose dependent inhibition of
human platelet aggregation by RGD-SAK was also indi-
cated (Fig. 5). The inhibitory effect of RGD-SAK was com-
parable to RGD-peptide alone.
Discussion
In this study, we report the construction and evaluation of
a new class of bifunctional proteins consisting of two
functional modules, RGD and SAK. To develop the novel
SAK variant designated RGD-SAK with platelet-targeted
thrombolytic and antiplatelet aggregation activity, K35 in
SAK was substituted with Arg to constitute a RGD motif,
which was testified to be recognized by the activated
GPIIb/IIIa. As three-dimensional structures of SAK and its
ternary complex with µPG (micro-plasminogen) have
Table 1: The kinetics of equimolar mixture of human plasmin 
with RGD-SAK
Km (µM) kcat (s-1)k cat/Km (µM-1s-1)
SAK 0.39 ± 0.03 0.015 ± 0.002 0.033 ± 0.003
RGD-SAK 0.78 ± 0.05 0.031 ± 0.001 0.037 ± 0.005
Data obtained from three experiments.
Fibrin and platelet binding assay Figure 3
Fibrin and platelet binding assay. (A) The quality of 
RGD-SAK absorbed by fibrin was similar to that of SAK. 
Data represent means ± SD obtained form three independ-
ent experiments. (B) ELISA was taken to measure the 
OD450, which represented the quantity of SAK or RGD-
SAK bound to the active platelet. The statistical differences 
are significant for each tested concentration (RGD-SAK vs 
SAK, P < 0.01). The means ± SD came from three separate 
experiments.BMC Molecular Biology 2007, 8:88 http://www.biomedcentral.com/1471-2199/8/88
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been resolved [9], various attempts to manipulate and
optimize the structure and function of SAK have been
reported [3-5]. One of them is to construct a targeted
thrombolytic agent. In some research, the Arg-Gly-Asp
(RGD) peptide was constructed in the SAK due to its affin-
ity with GPIIb/IIIa on the membrane of activated plate-
lets. However, the anticipated targeting effect to platelet-
rich clots was either partially or completely lost in some
studies, likely attributed to the positioning of RGD, which
should not be blocked by unfavorable spatial structure or
be cleaved off during the plasminogen activation process
[10,11]. By analysing the molecular modeling of the
mutants, our previous study [12] suggested that loop 1 in
SAK would be a rational introducing site for RGD.
Research [13] found that the secondary structure sheet 1
(G22-D33) of SAK can be connected with sheet 2 (N37-
I49) by loop 1, where the inserted RGD motif is supposed
to be exposed on the solvent accessible surface of the SAK
molecule and thus may allow access to the intergrin recep-
tors. In addition, loop 1 is far from the active cleft in the
SAK ternary complex [9], hence the mutation may have
little effect on the SAK complex activity.
For biochemical and biological analysis of RGD-SAK, a
convenient and effective method was developed to
express and purify the target protein, which also provided
an empirical basis for the establishment of standard oper-
ating procedure (SOP) for further large scale production.
Compared with the conventional induction by IPTG (Iso-
propyl β-D-1-thiogalactopyranoside) [14], the tempera-
ture inducible expression under the control of pL and pR
promoter in RGD-SAK expression is more feasible and
cost-saving for fermentation. By optimizing fermentation
condition, e.g. bacteria density and induction time, RGD-
SAK was present in intracellular soluble state instead of
inclusion body as reported previously [15], which is
highly desirable for further purification. To obtain the
highly purified and endotoxin-free protein, the cytosolic
fractions after homogenization were subjected to cation
chromatography and gel filtration to separate RGD-SAK,
followed by anion chromatography to eliminate endoxin.
The safety evaluation experiments testified that the highly
purified, sterilized preparations contained low endotoxin
Time course of fibrin clot and platelet-rich clot lysis assay Figure 4
Time course of fibrin clot and platelet-rich clot lysis 
assay. The relative clot turbidity was calculated by detecting 
the decrease of the absorbance at OD405. The clots were 
either acted with HBS or with SAK or RGD-SAK. The exper-
iments were repeated for three times. (A) T50% SAK and 
RGD-SAK calculated by the fibrin clot lysis assay were not 
significantly different at the final concentration 200 nM. (B) 
T50% was 118 ± 4.3 min for SAK and 57 ± 6.6 min for RGD-
SAK calculated by the platelet-rich clot lysis assay at the final 
concentration 200 nM.
Table 2: The time required to lyse 50% of fibrin clot or Platelet-rich clot (T50%) and the concentration required to obtain 50% clot lysis 
(C50) with SAK or RGD-SAK
Compound Concentration (nM) T50% of fibrin clot (min) T50% of platelet-rich 
clot (min)
C50 of fibrin clot lysis (nM) C50 of platelet-rich 
clot lysis (nM)
SAK 50 195 ± 8.7 198 ± 8.6 80 ± 8.5 200 ± 8.3
100 161 ± 9.3 166 ± 7.8
200 138 ± 8.5 123 ± 5.6
RGD-SAK 50 189 ± 9.9 93 ± 3.6 76 ± 8.3 38 ± 3.9
100 151 ± 6.3 59 ± 2.9
200 131 ± 9.7 33 ± 3.8
The activity of RGD-SAK or SAK was comparable in fibrin clot lysis assay at various corresponding concentrations.T50% was significantly shortened 
for each corresponding concentration (RGD-SAK vs SAK, P < 0.01). Results shown represent means ± SD from 6 clots for each concentration of 
SAK or RGD-SAK. C50 of fibrin clot lysis was not significantly different between SAK and RGD-SAK, while C50 of platelet-rich clot lysis caused by 
SAK was much higher than that of RGD-SAK (P < 0.01).BMC Molecular Biology 2007, 8:88 http://www.biomedcentral.com/1471-2199/8/88
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levels, and were devoid of acute toxicity, which is safe and
suitable for a more detailed clinical investigation.
Biochemical analysis indicated that RGD-SAK maintained
the similar structure and the fibrinolytic function of SAK.
The uniform N terminal sequence and similar CD spec-
trum suggested that these two molecules had similar
structure. The measurement with fibrin plate and fibrin
clot respectively revealed that the fibrinolytic activity of
RGD-SAK was at least equal to that of SAK. The study fur-
ther revealed that RGD-SAK can form a 1:1 RGD-SAK-
plasmin complex which displayed an amidolytic activity
comparable with that of the native SAK-plasmin binary
complex. The similar catalytic efficiencies determined by
kcat/Km of RGD-SAK in comparison with SAK revealed that
the specific plasiminogen activating potential of the
mutant remained almost intact. These above results indi-
cated that the RGD existence in SAK would not disrupt the
structure and the fibrinolytic function of SAK.
The platelet binding experiment indicated that RGD-SAK
could bind the activated platelet in a dose dependent
manner and with a higher affinity than SAK, which has
weak ability to bind the platelet. In the platelet-rich clot
lysis assay, the T50% values for RGD-SAK were significantly
shortened. Analysis of these T50% values revealed a signif-
icant increase in platelet-rich clot lysis rate by RGD-SAK
compared with SAK. Our data also demonstrated that
RGD-SAK did not lead to enhanced fibrin clot lysis under
in vitro conditions in comparison with SAK, which was
correlated with their similar ability to bind the fibrin clots.
By interpolation of the data of clot lysis assay, the C50 of
the two proteins was similar in fibrin-rich clot while the
C50 of RGD-SAK in platelet-rich clot was much shorter
than equalmole SAK. These results suggested that RGD-
SAK can target to the platelet-rich clots due to the direct
selective binding to the activated platelets but not to fibrin
which is also an important constituent of platelet-rich
clots. Based on these results, we can conclude that RGD-
SAK can accumulate on the platelet surface and thus
enrich the thrombolytic activity at the site of the throm-
bus. Hence, it is possible that RGD-SAK would be directly
targeted to thrombus in vivo because of their high affini-
ties to platelets, which can therefore lyse the platelet-rich
clots more efficiently than SAK due to the increased local
concentration on the thrombus. In addition, it would be
interesting to consider that the platelets themselves can
suppress clot lysis by mechanical cross-linking, promo-
tion of clot stability as well as release of fibrinolytic inhib-
itors [16]. Some recent in vivo studies [17,18] revealed that
fibrinolysis can be accelerated by conjunctive use of anti-
GP IIb/IIIa antibody. Hence, these findings imply that the
RGD-SAK may accelerate lysis of platelet-rich clots via
diverse mechanisms in vivo. Finally, it should be noted
that a retarded renal clearance of RGD-SAK can also be
expected due to its high affinities to the activated platelets
and thus the resulting prolongated duration of action
would allow use of low doses and/or less frequent admin-
istration of the agent. Therefore, if less RGD-SAK is
required to achieve the same degree of clot lysis as SAK,
The effects of SAK and RGD-SAK on platelet aggregation Figure 5
The effects of SAK and RGD-SAK on platelet aggregation. The means ± SD came from six independent experiments. 
Results are expressed as a percent inhibition in relation to platelets incubated with no recombinant proteins taken as 100%. 
The statistical differences between the inhibitory effects of RGD-SAK and SAK for each tested concentration are significant (P 
< 0.01).BMC Molecular Biology 2007, 8:88 http://www.biomedcentral.com/1471-2199/8/88
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the risk for side effects could also be minimized. We will
further test the speculation by pharmacological and phar-
macokinetic studies in vivo.
The use of RGD peptide as a platelet-targeted domain in
the design of SAK mutant offers RGD-SAK another poten-
tial advantage of antiplatelet aggregation. It is well known
that aggregation of blood platelets plays a pivotal role in
the formation of thrombus and the RGD peptide is a com-
ponent of ligands recognizing platelet intergrins [7,8].
Therefore, the protein containing RGD has the potential
ability to inhibit platelet aggregation and thus to be used
in the prevention of arterial rethrombosis. In the
antiplatelet aggregation assay in vitro, we have shown that
the addition of the RGD sequence to SAK resulted in
acquisition of the ability to prevent platelet aggregation.
In the present study, the RGD-SAK had obvious inhibitory
effects on different inducers (ADP or collagen or
thrombin)-induced platelet aggregation in a dose depend-
ent manner, while the SAK had almost no effect on plate-
let aggregation. Meanwhile, the efficiency of antiplatelet
aggregation by RGD-SAK was comparable with that of
RGD sequence alone. For ADP, collagen and thrombin are
the most powerful physiological inducers of platelet
aggregation after arterial injury and during rethrombosis,
so the present data indicated that RGD-SAK possessed the
ability to block platelet aggregation and hence should be
more effective than SAK in preventing the formation of
rethrmobosis after successful thrombolytic therapy,
which would also be worthy of further research in vivo.
Noticeably, for the thrombolysis and rethrombosis in vivo
is a complex process, thrombin was also found to be
closely related to this action. So, it's very interesting to
speculate that the addition of antithrombin functional
element to SAK may also accelerate the successful lysis of
the thrombus as well as the protection against rethrombo-
sis. Recently such a protein has been synthesized by Szem-
raj et al. [19], which cued in us that fusion antithrombin
element with RGD-SAK may form a even more potent and
faster thrombolytic agent with anti-rethrombosis proper-
ties than SAK. We will further manipulate and screen the
rational SAK mutant on the purpose in the future.
Conclusion
In conclusion, the present study established the large scale
expression and preparative purification method for RGD-
SAK. The results of the in vitro study revealed that the puri-
fied mutant of SAK possessed the bifunction to target
platelet-rich clots and to block platelets aggregation, and
thus may be a more potent clot-dissolving agent for
thrombolytic therapy compared with SAK.
Methods
Construction of E. coli expression vector of RGD-SAK
The DNA fragment encoding RGD-SAK was obtained by
substituting K35 with Arg to constitute a RGD motif using
PCR-based mutagenesis on the template of pSTE-SAK con-
structed in our previous research [12]. in which gene
encoding the mature region of SAK. The desired mutant
was confirmed by DNA sequencing and cloned into
expression vector pLY-4. Cytosolic expression was
obtained by introducing the recombinant plasmids PLY-
4-DGR into E coli JF1125 under the temperature induci-
ble pL and pR promoter.
Large scale expression and preparative purification of 
RGD-SAK
Two-step fermentations were used in the protein expres-
sion. Fourteen-liter M9CA medium was inoculated with 1
L of an overnight bacteria culture in LB medium in a 20 L
fermentor (Bioengineering, Swiss), and was grown at
30°C for 5 h. The culture was then transferred into a 300
L fermentor with 200 L M9CA medium, and grew at 30°C
for another 5 h. The soluble expression of RGD-SAK was
induced at 42°C for 2.5 h before harvesting. For RGD-SAK
purification, the cell pellet collected by centrifugation was
homogenized with a high pressure homogenizer (APV-
2000, Denmark). The supernatant obtained was purified
by Chromatography system (AKTA Explore, GE) at 4°C
on a 12.5 × 40 cm column of SP-Sepharose (Amersham-
Pharmacia Biotech, USA), equilibrated with 0.02 M NaAc-
HAc (pH 5.6), and eluted with a linear salt gradient
(0.01–1 M NaAc-HAc-NaCl). RGD-SAK containing frac-
tions were further purified by 12.5 × 100 cm Sephadex G-
50 (Amersham-Pharmacia Biotech, USA) and concen-
trated by application on a 7.5 × 50 cm column of Q-
Sepharose (Amersham-Pharmacia Biotech, USA) with
stepwise elution (0.01–1.0 M PB-NaCl). The RGD-SAK
containing fractions were pooled and adjusted to 1 mg/
ml, and the material was sterilized by filtration through a
0.22  µm Millipore filter. Purified recombinant protein
was analyzed by 15% SDS-PAGE. Rabbit polyclonal anti-
SAK antibodies were used for the detection of RGD-SAK
by western blot analysis.
Physicochemical characterization of RGD-SAK
The purity of this complex was confirmed by High-per-
formance liquid chromatography (HPLC). The purified
and concentrated samples were applied to a reversed
phase C18 column (3.5 µm, 2.1 × 100 mm) (Waters, Mil-
ford, MA, USA), using a 2690 Alliance HPLC (Waters, Mil-
ford, MA, USA). Samples were eluted with a 0.1%
HCOOH (H2O): 0.1% HCOOH (CH3OH) gradient,
100:0 to 0:100 in 30 min at a flow rate of 0.2 ml/min. Pro-
tein mass spectrometry analysis was performed using
Matrix-assisted Laser Desorption Ionization-Time of
Flight (MALDITOF) Mass (Waters, Milford, MA, USA).BMC Molecular Biology 2007, 8:88 http://www.biomedcentral.com/1471-2199/8/88
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Mass spectra of the samples were obtained using a micro-
mass spectrometer equipped with electrospray ionization
(ESI) source.
The structural analysis of the protein was performed using
N-terminal sequencing and Circular dichroism spectros-
copy (CD spectra). Briefly, Purified recombinant protein
were transferred to a polyvinylidene difluoride (PVDF)
membrane by electroblotting for N-terminal sequencing
by automated Edman degradation procedure as described
by Matsudaira [20]. The obtained sequence was compared
with the cDNA-deduced polypeptide sequence. The sec-
ondary structure of the protein was estimated from spec-
tral simulations based on reference CD spectra of Yang et
al [21].
Biological analysis of RGD-SAK
The methodology for evaluation of endotoxin contamina-
tion, bacterial sterility, and acute toxicity in mice of RGD-
SAK was established according to Collen D et al. [22].
Purified preparations of RGD-SAK were planted on agar
plates, which were then incubated under aerobic and
anaerobic conditions, on McConkie and chocolate-agar
media, and in thioglycolate and tryptic soy broth media to
test bacterial sterility. The limulus amoebocyte lysate
assay was used to determine the endotoxin contamination
of the preparations according to the instructions of the
manufacturer (sFDA). The acute toxicity of RGD-SAK
preparations versus saline was evaluated by intravenous
bolus injection of 200 µl of the purified sterilized material
at a dose of 3 mg per mice in 6 mice every group (All ani-
mals care and animal experimentation involved in this
work were in accordance with NIH guidelines and the
approved procedures of the Institutional Animal Use and
Care Committee at Fudan University.). The animals were
observed for living state and acute reactions (tachypnea,
restlessness, stupor) during an 8-day observation period.
Fibrinolytic activity assay on fibrin plate
Fibrinolytic activity of SAK and RGD-SAK was measured
on fibrin plate [23]. Petri dishes containing 0.5% agrose,
0.055 IU/ml thrombin, 5.5 µg/ml plasminogen (PG) and
0.52 µg/ml fibrinogen were prepared. On this solidified
fibrin plate, wells of equal diameter were punched and 10
µl/well of diluted appropriate concentration of SAK (1000
IU/ml, SFDA) or RGD-SAK was added and kept at 37°C
for 16 h. The diameter of the halo around the well was
measured to calculate the functional activity of SAK or
RGD-SAK.
Activation of human plasminogen
The kinetics of plaminogen activation was determined
according to Schlott B et al. [24]. Plasminogen was incu-
bated with equimolar SAK or RGD-SAK at 37°C for 1 h to
generate the SAK-plasmin or RGD-SAK-plasmin bimo-
lecular complex. The performed activator complex (final
concentration 10 nM) was then mixed with different con-
centration of plasminogen (final concentration 0.625 µM,
1.25 µM, 2.5 µM, 5 µM, 10 µM) and generation of plas-
min was continuously monitored at 405 nm with S-2251
(3 mM). The kinetics constants were determined from
Lineweaver-Burk plots.
Measurement of fibrin binding activity
Microtiter plate was coated overnight with cross-linked
fibrin as described by Wu et al. [25]. Briefly, Fibrinogen (5
µg/ml) was added into the wells and left overnight at 4°C,
then blocked with 2 mg/ml BSA for 2 h. The fibrinogen
was incubated with PBS containing human thrombin (1
NIH unit/ml) and CaCl2 (20 mM) for 2 h at 37°C to form
cross-linked state. The fibrin was partially digested with
plasmin at 1 pmol/well for 10 min at the room tempera-
ture, then the microplate was washed with PBST to
remove unbound plasmin. SAK or RGD-SAK in PBST con-
taining 3% BSA was added into the wells at a final concen-
tration of 200 nM for 2 h at the room temperature. After
washing the plate with PBST for three times, unbound
materials were removed. The SAK or RGD-SAK retained
on the well was bound with polyclonal antibodies against
SAK and HRP-conjugated anti-mouse secondary antibod-
ies orderly. Substrate solution of TMB was added to
develop the color and was stopped with 1 M H2SO4. The
optical density was read at 450 nm for 30 min. As a blank,
some wells were coated only with PBS but treated other-
wise the same. The experiment was performed three times
for both SAK and RGD-SAK.
Fibrin clot lysis assay
Ninety-six-well microtiter plates were used for clot lysis
assay according to the method reported previously [10].
The wells were loaded with thrombin (0.6 NIH unit/ml),
human fibrinogen (1 mg/ml) and 20 mM CaCl2 in HBS
buffer (10 mM HEPES, 130 mM NaCl, pH 7.4) and the
polymerizing fibrin solution were incubated for 3 h at a
room temperature. The clots formed were washed with
HBS, and then layered with a solution containing 1.5 µM
hPlg and SAK, or RGD-SAK at varying concentrations (50,
100, 200 nM). After 30 min of incubation at room tem-
perature, the surface of the clots was washed with HBS and
the washed clots were layered with 1.5 µM hPlg in HBS.
The turbidity of the wells was measured as the optical den-
sity (OD) at 405 nm every 6 minutes, using a microtiter
plate reader (Perkin Elmer 1420, VICTOR 3) until com-
pletion. T50% for clot lysis, which represented the time to
achieve a 50% lysis of the fibrin clot, was calculated from
the OD/time data. The concentration of fibrinolytic agent
required to obtain 50% clot lysis in 3 hours (C50) was
determined from plots of percent versus the concentration
of test compound. Duplicate wells were prepared for each
concentration of clot lysis of SAK or RGD-SAK in eachBMC Molecular Biology 2007, 8:88 http://www.biomedcentral.com/1471-2199/8/88
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experiment, and the experiment was repeated three times.
As a control, some clots were layered only with HBS but
treated otherwise the same.
Measurement of platelet binding activity
An ELISA method was used to assess the platelet binding
activity of SAK and RGD-SAK [26]. The activated human
platelets induced by thrombin solution (0.2 IU/ml) were
transferred to microtiter plate. SAK or RGD-SAK in the
buffer A (50 mM Tris-HCl, 100 mM NaCl, 2 mM CaCl2,
pH 7.4) was added to the wells at a final concentration of
25 nM, 50 nM, 100 nM, or 200 nM. After incubated in
37°C for 3 h, the plate was washed with PBST for three
times to remove the unbound materials. SAK or RGD-SAK
retained on the well was probed with polyclonal antibod-
ies against SAK [27] followed by horseradish peroxidase
(HRP)-conjugated anti-mouse secondary antibodies. The
amount of HRP retained was assessed by using TMB
(Tetrabenzidine) as HRP substrate. Color development
was determined at 450 nm using a microplate reader (Per-
kin Elmer 1420, VICTOR 3). T50% for clot lysis, which rep-
resented the time to achieve a 50% lysis of the platelet-
rich clot, was calculated from the OD/time data. The con-
centration of fibrinolytic agent required to obtain 50%
clot lysis in 2 hours (C50) was determined from plots of
percent versus the concentration of test compound. As a
control, some wells were layered only with PBS but treated
otherwise the same. The experiment was repeated three
times.
Platelet-rich clot lysis assay
Platelet-rich clot was formed using the modified proce-
dure described by zhang et al. [26]. Clotting was initiated
by mixing human thrombin (to 0.6 NIH unit/ml), human
fibrinogen (1 mg/ml) and CaCl2 (to 20 mM) in human
platelet. Each clot in the microtiter plate was layered with
100 µl aliquot containing freshly mixed hPlg (1.5 µM)
and varied concentration of SAK or RGD-SAK (50, 100,
200 nM). After 30 min the surface of each clot was washed
three times with HBS to remove unbound SAK or RGD-
SAK and 100 µl hPlg (1.5 µM) were layered on each clot.
The clot lysis process was monitored by measuring the tur-
bidity using a microtiter plate reader. Duplicate wells were
taken in each one of the three repeated experiments. As a
control, some clots were layered only with HBS but
treated otherwise the same.
Inhibition of platelet aggregation
Platelet aggregation assay was performed with a modified
method described by Seymour et al. [28]. Isolated Plate-
let-rich plasma (PRP) was incubated for 15 min at 37°C
with either SAK (diluted by saline, 2.5, 5, 10, 20, 40 µM)
or equimolar concentrations of RGD-SAK or RGD (Sigma,
USA) prior to the platelet aggregation stimulation with
ADP (10 µM) or collagen (1 µg/ml) or thrombin 1 U/ml.
The aggregation response was recorded using a dual-chan-
nel aggregometer (APACT Labor, Germany) and aggrega-
tion results were expressed as percent inhibition of
platelet aggregation. Saline was choosed to be control.
Statistical analysis
Data are expressed as means ± SD. One-way analysis of
variance (ANOVA) or student's t  test was used where
applicable. The differences with P-values < 0.05 were con-
sidered statistically significant.
Authors' contributions
HSC and WM carried out most of the experimental work
described in this paper and drafted the manuscript. YLZ
assisted with the expression studies and data analysis.
HBS carried out many molecular biology studies. HYS
participated in design and coordination of the study and
revised the manuscript in form and content. All authors
read and approved the final manuscript.
Acknowledgements
We thank Prof. Xinyuan Liu (Shanghai Institute of Biochemistry, Chinese 
Academic of Sciences) for kindly providing the expression vector pLY-4 and 
E. Coli JF1125. This wok was supported by National 863 high-technology 
program (103-13-01-02, 2001) and the key Project from the shanghai Sci-
ence and Technology Committee of China (No. 05DZ19303).
References
1. Collen D, Van de Werf F: Coronary thrombolysis with recom-
binant staphylokinase in patients with evolving myocardial
infarction.  Circulation 1993, 87(6):1850-1853.
2. Vanderschueren S, Stockx L, Wilms G, Lacroix H, Verhaeghe R, Ver-
mylen J, Collen D: Thrombolytic therapy of peripheral arterial
occlusion with recombinant staphylokinase.  Circulation 1995,
92(8):2050-2056.
3. Armstrong PW, Burton J, Pakola S, Molhoek PG, Betriu A, Tendera
M, Bode C, Adgey AA, Bar F, Vahanian A, Van de Werf F, CAPTORS
II Investigators: Collaborative Angiographic Patency Trial Of
Recombinant Staphylokinase (CAPTORS II).  Am Heart J 2003,
146(3):484-488.
4. Mazur W, Kaluza G, Kleiman NS: Antiplatelet therapy for treat-
ment of acute coronary syndromes.  Cardiol Clin 1999,
17(2):345-357.
5. Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang IK, Holt
R, Fallon JT, Collen D: Comparative effects of aspirin, a syn-
thetic thrombin inhibitor and a monoclonal antiplatelet glyc-
oprotein IIb/IIIa antibody on coronary artery reperfusion,
reocclusion and bleeding with recombinant tissue-type plas-
minogen activator in a canine preparation.  J Am Coll Cardiol
1990, 16(3):714-722.
6. Ruoslahti E: RGD and other recognition sequences for
integrins.  Annu Rev Cell Dev Biol 1996, 12:697-715.
7. Yamada T, Shimada Y, Kikuchi M: Integrin-specific tissue-type
plasminogen activator engineered by introduction of the
Arg-Gly-Asp sequence.  Biochem Biophys Res Commun 1996,
228(2):306-311.
8. Ruoslahti E, Pierschoacher MD: New perspectives in cell adhe-
sion: RGD and integrins.  Science 1987, 238(4286):491-497.
9. Parry MA, Fernandez-Catalan C, Bergner A, Huber R, Hopfner KP,
Schlott B, Guhrs KH: The ternary microplasmin-staphyloki-
nase-microplasmin complex is a proteinase-cofactor-sub-
strate complex in action.  Nat Struct Biol 1998, 5(10):917-923.
10. Wu SC, Castellino FJ, Wong SL: A fast-acting, modular-struc-
tured staphylokinase fusion with kringle-1 from human plas-
minogen as the fibrin-targeting domain offers improved clot
lysis efficacy.  J Biol Chem 2003, 278(20):18199-18206.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Molecular Biology 2007, 8:88 http://www.biomedcentral.com/1471-2199/8/88
Page 11 of 11
(page number not for citation purposes)
11. Van Zyl WB, Pretorius GH, Lamprecht S, Roodt JP, Kotze HF:
PLATSAK, a potent antithrombotic and fibrinolytic protein,
inhibits arterial and venous thrombosis in a baboon model.
Thromb Res 2000, 98(5):435-433.
12. Su HB, Zhang YG, He JT, Mo W, Zhang YL, Tao XM, Song HY: Con-
struction and characterization of novel staphylokinase vari-
ants with antiplatelet aggregation activity and reduced
immunogenecity.  Acta Biochim Biophys Sin 2004, 36(5):336-342.
13. Rabijns A, de Bondt HL, de Ranter C: Three-dimensional struc-
ture of staphylokinase, a plasminogen activator with thera-
peutic potential.  Nat Struct Biol 1997, 4(5):357-360.
14. Schlott B, Hartmann M, Guhrs KH, Birch-Hirschfeid E, Pohl HD,
Vanderschueren S, Van de Werf F, Michoel A, Collen D, Behnke D:
High yield production and purification of recombinant sta-
phylokinase for thrombolytic therapy.  Biotechnology (N Y) 1994,
12(2):185-189.
15. Cheng A, Song G, Su HB, Yu M, Li YY, Song HY: The renaturation
and purification of RGD-staphylokinase by gel filtration.
Sheng Wu Gong Cheng Xue Bao 2002, 18(6):693-697.
16. Konstantinides S, Schafer K, Thinnes T, Loskutoff DJ: Plasminogen
activator inhibitor-1 and its cofactor vitronectin stabilize
arterial thrombi after vascular injury in mice.  Circulation 2001,
103(4):576-583.
17. Collet JP, Montalescot G, Lesty C, Soria J, Mishal Z, Thomas D, Soria
C: Disaggregation of in vitro preformed platelet-rich clots by
abciximab increases fibrin exposure and promotes fibrinoly-
sis.  Arterioscler Thromb Vasc Biol 2001, 21(1):142-148.
18. Huang TC, Jordan RE, Hantgan RR, Alevriadou BR: Differential
effects of c7E3 Fab on thrombus formation and rt-PA-medi-
ated thrombolysis under flow conditions.  Thromb Res 2001,
102(5):411-425.
19. Szemraj J, Walkwoiak B, Kawecka I, Janiszewska G, Buczko W, Bar-
tkowiak J, Chabielska E: A new recombinant thrombolytic and
antithrombotic agent with higher fibrin affinity – a staphy-
lokinase variant. I. In vitro study.  J Thromb Haemost 2005,
3(10):2156-2165.
20. Matsudaira P: Sequence from picomole quantities of proteins
electroblotted onto polyvinylidene difluoride membranes.  J
Biol Chem 1987, 262(21):10035-10038.
21. Yang YW, Teng CC: Circular dichroism and fluorescence stud-
ies of polyomavirus major capsid protein VP1.  J Protein Chem
1998, 17(1):61-71.
22. Collen D, Moreau H, Stockx L, Vanderschueren S: Recombinant
staphylokinase variants with altered immunoreactivity. II:
Thrombolytic properties and antibody induction.  Circulation
1996, 94(2):207-216.
23. Bi Q, Cen X, Huang Y, Zhu S: Construction and characterization
of trifunctional single-chain urokinase-type plasminogen
activators.  Eur J Biochem 2002, 269(6):1708-1713.
24. Schlott B, Gührs KH, Hartmann M, Röcker A, Collen D: Staphyloki-
nase requires NH2-terminal proteolysis for plasminogen
activation.  J Biol Chem 1997, 272(9):6067-6072.
25. Wu SC, Yeung JC, Duan Y, Ye R, Szarka SJ, Habibi HR, Wong SL:
Functional production and characterization of a fibrin-spe-
cific single-chain antibody fragment from Bacillus subtilis:
effects of molecular chaperones and a wall-bound protease
on antibody fragment production.  Appl Environ Microbiol 2002,
68(7):3261-3269.
26. Zhang L, Wang J, Yu M, Ru B: Functional properties of a recom-
binant chimeric plasminogen activator with platelet-tar-
geted fibrinolytic and anticoagulant potential.  Mol Genet
Metab 2004, 82(4):304-311.
27. Ye R, Kim JH, Kim BG, Szarka S, Sihota E, Wong SL: High-level
secretory production of intact, biologically active staphyloki-
nase from Bacillus subtilis.  Biotechnol Bioeng 1999, 62(1):87-96.
28. Seymour JL, Henzel WJ, Nevins B, Stults JT, Lazarus RA: Decorsin.
A potent glycoprotein IIb-IIIa antagonist and platelet aggre-
gation inhibitor from the leech Macrobdella decora.  J Biol
Chem 1990, 265(17):10143-10147.